Association between Arg399Gln polymorphysim of XRCC1 gene and sensitivity to platinum-based chemotherapy in advanced gastric cancer: A meta-analysis / 肿瘤

ABSTRACT

Objective: To quantitatively evaluate the association between Arg399Gln polymorphysim of X-ray repair cross-complementing group 1 (XRCC1) gene and sensitivity to platinum-based chemotherapy in advanced gastric cancer. Methods: The relevant published studies were retrieved from PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature Data, Chinese Science and Technology Periodicals Data and WanFang databases with computer. Clinical response [complete response (CR) + partial response (PR)] was employed to estimate chemosensitivity. Odds ratio (OR) and its 95% confidence interval (CI) were calculated. The statistical analysis was conducted by the RevMan 5.2 and STATA 12.0 softwares. Results: A total of 1 068 cases from 8 trials were included in the analysis. The results of Meta-analysis showed no statistical significance between XRCC1 Arg399Gln polymorphism and clinical response among all genotypes (GA vs GG: OR = 0.71, 95% CI: 0.50-1.01; AA vs GG: OR = 0.76. 95% CI: 0.43-1.36; GA+GG vs AA: OR = 1.08, 95% CI: 0.63-1.86; GA+AA vs GG: OR = 0.67, 95% CI: 0.43-1.05) as well as in subgroup of Asian people (GA+GG vs AA: OR = 0.64, 95% CI: 0.35-1.16). After the sensiticity analysis based on different detection methods, the result revealed that there was a significant difference between genotype GA+AA vs GG (OR = 0.58, 95% CI: 0.40-0.86), especially in subgroup of Asian people (GA+AA vs GG: OR = 0.53, 95% CI: 0.37-0.75). Conclusion: In this Meta-analysis, polymorphism of XRCC1 Arg399Gln may be associated with low sensitivity to platinum-based chemotherapy in gastric cancer. Copyright© 2014 by TUMOR.